In Use Product Safety Assessment Report For Fiasp® (Insulin Aspart)

The addition of another insulin aspart product to the two already available has the potential to create further confusion in the prescribing, dispensing, and administration of these products. This review aims to summarise safety concerns that should be considered.


Specialist Pharmacy Service